Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest

• Главные авторы: Alexander Egeberg (Автор), Denis Jullien (Автор), Kristian Gaarn Du Jardin (Автор), Diamant Thaçi (Автор)
• Формат: ‌
• Опубликовано: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Background Five-year tildrakizumab safety data have been reported as exposure-adjusted incidence rates (EAIRs) of patients with events per 100 patient-years (PYs) of exposure. Objectives To present 5-year safety data from reSURFACE 1/2 phase 3 trials as EAIRs of events per 100 PYs of exposure, and t...